Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study
Open Access
- 22 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 12 (3), 943-954
- https://doi.org/10.1007/s13300-021-01016-y
Abstract
Introduction Despite expert consensus guidelines, data is scarce on how to switch patients with type 2 diabetes when treatment with glucagon-like peptide 1 (GLP-1) receptor agonists is not effective and whether a switch to semaglutide brings any benefit on glucose and weight control for patients with type 2 diabetes. Methods Retrospective cohort analysis of patients with type 2 diabetes who were switched from any GLP-1 agonist in a stable dose to subcutaneously administered semaglutide. Primary endpoint was change of glycated haemoglobin (HbA1c) at 6 months. Secondary endpoints were weight, body mass index (BMI), heart rate, blood pressure and adverse events. Results In total, 77 patients (median age 65 years) with long-standing type 2 diabetes (median 15 years, median HbA1c 8.4%/68 mmol/l, median BMI 33 kg/m2) were included. HbA1c was significantly lower 6 months after switching to semaglutide (7.3%; 56 mmol/l). Median body weight was significantly lower at 3 months (94 kg) and 6 months (93 kg) compared to baseline (98 kg). An equipotential dose switch of semaglutide was used in 61 patients (79%) and a stepwise initiation approach was used in 16 patients (21%). Both treatment regimens improved glucose control and weight. Side effects occurred in 28 patients (36%). Conclusion Switching to semaglutide from established GLP-1 analogue therapy improved HbA1c and body weight. Both equipotential and stepwise dosing initiation appear to be effective and well tolerated.This publication has 17 references indexed in Scilit:
- Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trialsDiabetes Research and Clinical Practice, 2018
- Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approachDiabetes, Obesity and Metabolism, 2018
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without MetforminDiabetes Care, 2018
- Glucagon-like peptide 1 in health and diseaseNature Reviews Endocrinology, 2018
- GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 DiabetesJournal of Diabetes Research, 2018
- A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian SubjectsAdvances in Therapy, 2018
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical TrialDiabetes Care, 2018
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trialThe Lancet Diabetes & Endocrinology, 2018
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 DiabetesDiabetes Care, 2015